Satralizumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 180 publications
Updates on the Acute and Maintenance Management of Optic Neuritis Including Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody Disease.
Journal: Neurologic clinics
Published: April 01, 2026
Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 24, 2026
Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.
Journal: Internal medicine (Tokyo, Japan)
Published: February 11, 2026
Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: January 21, 2026
Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 06, 2026
Place of anti-IL6R in the therapeutic strategy in NMOSD-AQP4+, MOGAD, and NMOSD double-seronegative patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 17, 2025
Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.
Journal: International journal of molecular sciences
Published: December 14, 2025
What is in the Neuromuscular Junction Literature?
Journal: Journal of clinical neuromuscular disease
Published: December 03, 2025
Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System.
Journal: Intractable & rare diseases research
Published: October 11, 2025
Last Updated: 04/28/2026